...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients
【24h】

Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients

机译：非同源，肥胖和病态肥胖患者Meropenem人口药代动力学和药效学

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The study objective was to evaluate meropenem population pharmacokinetics and pharmacodynamics in nonobese, obese, and morbidly obese patients. Forty adult patients-11 nonobese (body mass index [BMI] < 30 kg/m(2)), 9 obese (30 kg/m(2) <= BMI < 40 kg/m(2)), and 20 morbidly obese (BMI >= 40 kg/m(2))-received meropenem 500 mg every 6 hours (q6h), q8h, or q12h or 1 g q6h or q8h, infused over 0.5 hour. Population pharmacokinetic modeling was performed using NONMEM, and 5000-patient Monte-Carlo simulations were performed to calculate probability of target attainment (PTA) for 5 dosing regimens, infused over 0.5 and 3 hours, using fT > MIC of 40%, 54%, and 100% of the dosing interval. A 2-compartment linearelimination model best described the serum concentration-time data, and creatinine clearance was significantly associated with systemic clearance. Pharmacokinetic parameters were not significantly different among patient groups. In patients with creatinine clearances >= 50mL/min, all simulated dosing regimens achieved > 90% PTA at 40% fT > MIC in all patient groups at MICs <= 2 mg/L. Only 500 mg q8h, infused over 0.5 hour, did not achieve > 90% PTA at 54% fT> MIC in nonobese and morbidly obese patients. At 100% fT> MIC, 1 g q6h and 2 g q8h, infused over 3 hours, reliably achieved > 90% PTA in all patient groups. Meropenem pharmacokinetics are comparable among nonobese, obese, and morbidly obese patients. Standard dosing regimens provide adequate pharmacodynamic exposures for susceptible pathogens at 40% and 54% fT> MIC, but prolonged infusions of larger doses are needed for adequate exposures at 100% fT> MIC. Dosage adjustments based solely on body weight are unnecessary.
机译：研究目标是评估非同源，肥胖和病态肥胖患者的梅洛涅姆人口药代动力学和药效学。 40例成年患者-11非（体重指数[BMI] <30kg / m（2）），9肥胖（30kg / m（2）<= bmi <40kg / m（2）），和20个病态肥胖（BMI> = 40kg / m（2）） - 每6小时（Q6H），Q8H或Q12H或1g Q6H或Q8H或1g Q6H或Q8H接收梅洛宁500mg，净化0.5小时。使用非谋区进行人口药代动力学建模，并进行5000例骨髓 - 卡罗模拟以计算靶培养方案（PTA）的概率为5个给药方案，注入0.5和3小时，使用FT> MIC为40％，54％，54％，和100％的给药间隔。 2室线性化模型最能描述血清浓度 - 时间数据，肌酐清除与系统间隙显着相关。患者组中药代动力学参数没有显着差异。在患有肌酐间隙的患者中> = 50ml / min，所有模拟给药方案在MICS <= 2 mg / L的所有患者组中达到40％FT> MIC。只有500毫克Q8H，注入0.5小时，未在非伯爵和病态肥胖患者中达到54％的麦克风，麦克风的54％。在100％ft> mic，1g q6h和2g q8h，注入3小时内，可靠地达到所有患者组中的90％pta。梅洛涅姆药代动力学在非obese，肥胖和病态肥胖患者之间具有可比性。标准剂量方案为易感病原体提供了40％和54％的FT> MIC的足够药物动力学曝光，但需要较大剂量的延长输注，以在100％FT> MIC下进行足够的曝光。不需要基于体重的剂量调整。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号